The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The safety and efficacy of the Syk inhibitor sovleplenib in heavily pre-treated Hodgkin lymphoma
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on a study investigating the safety and efficacy of sovleplenib, a spleen tyrosine kinase (Syk) inhibitor, in patients with heavily pre-treated Hodgkin lymphoma (HL) (NCT03779113). The safety profile was manageable, and the agent successfully induced durable complete remission (CR) and measurable residual disease (MRD) eradication in a proportion of patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role: Genentech/Roche, ADC Therapeutics, TG Therapeutics, Kite, a Gilead company. Research Funding: AstraZeneca, ALX Oncology, Gilead Sciences. Travel, Accommodations, Expenses: SOBI.
